A weekly injection for diabetes generally refers to glucagon-like peptide-1 (GLP-1) receptor agonist glucose-lowering drugs, such as dulaglutide and simethicone, which are commonly administered by subcutaneous injection once a week, starting with a small dose. GLP-1 receptor agonists are a new type of hypoglycemic agent that lowers blood glucose through a mechanism that stimulates insulin secretion and decreases glucagon secretion. It usually requires only one injection per week, subcutaneously, and is easy to administer. Common adverse reactions to GLP-1 receptor agonists are gastrointestinal disturbances such as nausea, vomiting, and diarrhea. It is contraindicated in patients who are allergic to the components of the drug, have a history or family history of medullary thyroid cancer, unexplained recurrent pancreatitis, and severe gastrointestinal dysfunction. GLP-1 receptor agonist is easy to use, but it is a prescription drug, which needs to be used strictly under the guidance of a physician, and should not be used without authorization.